Sun Pharmaceutical Industries Ltd’s new alopecia treatment, Leqselvi (Deuruxolitinib), recently approved by the US Food and Drug Administration (FDA), is encountering legal challenges that may delay its market debut. A motion for a preliminary injunction has been filed in a US court to block the drug’s launch, putting the company’s planned rollout on hold.
Due to these ongoing legal…
